Nektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues - Barron's

Nektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues  Barron's

Shares of biotech firm Nektar Therapeutics collapsed after the company revealed in an earnings call that there had been manufacturing issues in two batches of ...

View full coverage on Google News

from Top stories - Google News August 09, 2019 at 06:59PM

Comments

Popular posts from this blog

Jared Leto Was Responsible for the "We Live in a Society" Line in the 'Zack Snyder's Justice League' Trailer - /FILM

How to keep Amazon, Apple, and Google from listening to your Alexa, Siri, and Assistant recordings - TechHive

Exclusive: IAEA found uranium traces at Iran 'atomic warehouse' - diplomats - Reuters